Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Corvus Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 49 | 50 | +1 |
| Shares | 20.4M | 23.7M | +3.28M (+16.1%) |
| Value | $62.8M | $63.2M | +$396.0K (+0.6%) |
New holders (4)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| EcoR1 Capital, LLC | 3,579,377 | $9.56M | 0.36% |
| Verition Fund Management LLC | 41,788 | $112.0K | 0.00% |
| State Street Corp | 29,600 | $79.0K | 0.00% |
| Parallel Advisors, LLC | 20 | $0 | 0.00% |
Sold out (3)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Bank Julius Baer & Co. Ltd, Zurich | 336,748 | $1.04M |
| Gsa Capital Partners LLP | 95,613 | $294.0K |
| Charles Schwab Investment Management Inc | 13,830 | $43.0K |